Open Access

Clinical and prognostic significance of signal transducer and activator of transcription 3 and mucin 1 in patients with non-small cell lung cancer following surgery

  • Authors:
    • Zhi‑Gang Sun
    • Min Zhang
    • Fei Yang
    • Wei Gao
    • Zhou Wang
    • Liang‑Ming Zhu
  • View Affiliations

  • Published online on: January 25, 2018     https://doi.org/10.3892/ol.2018.7858
  • Pages: 4278-4288
  • Copyright: © Sun et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: HTML 0 views | PDF 0 views     Cited By (CrossRef): 0 citations

Abstract

Signal transducer and activator of transcription 3 (STAT3) and mucin 1 (MUC1) are associated with development, progression and a poor prognosis in several types of cancer. The present study investigated the levels of STAT3 and MUC1 in patients with non‑small cell lung cancer (NSCLC) following surgery. In total, 98 patients with NSCLC were enrolled into the study. STAT3, phosphorylated (p)‑STAT3 and MUC1 expression in NSCLC specimens obtained from patients were investigated using immunohistochemical analysis. Enumeration results were analyzed using the χ2 test or Fisher's exact probability test. Spearman's rank correlation was used to analyze correlations between STAT3, p‑STAT3 and MUC1 expression. Univariate analysis was conducted using the Kaplan‑Meier estimator curve method and Cox regression multivariate analysis was performed in order to determine prognostic factors. Results demonstrated that STAT3 and p‑STAT3 expression was identified in 82 and 51 patients, respectively. Furthermore, the expression of MUC1 was identified in 61/98 cases (62.2%) and STAT3 expression was significantly associated with pathological tumor‑node‑metastasis stage (pTNM; P<0.01). p‑STAT3 expression was associated with pathological type (P<0.01), pathological lymph nodes (pN; P<0.01) and pTNM (P<0.05). MUC1 expression was associated with pathological type (P<0.05), pathological tumor pT (P<0.05), pN (P<0.01) and pTNM (P<0.01). STAT3 expression was positively associated with p‑STAT3 expression (P<0.05) and p‑STAT3 expression was positively associated with MUC1 expression (P<0.01). Overall, the results identified that the 3‑year survival rate was 56.1% and was significantly associated with the degree of differentiation (P<0.05), pT (P<0.01), pN (P<0.01), pTNM stage (P<0.01), p‑STAT3 expression (P<0.01) and MUC1 expression (P<0.05). Results obtained from the Cox multivariate regression analysis demonstrated that pN and p‑STAT3 expression were independent factors associated with the 3-year survival rate.

References

1 

Li Y, Wei S, Wang J, Hong L, Cui L and Wang C: Analysis of the factors associated with abnormal coagulation and prognosis in patients with non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 17:789–796. 2014.(In Chinese). PubMed/NCBI

2 

Sun W, Song L, Ai T, Zhang Y, Gao Y and Cui J: Prognostic value of MET, cyclin D1 and MET gene copy number in non-small cell lung cancer. J Biomed Res. 27:220–230. 2013.PubMed/NCBI

3 

Molina JR, Yang P, Cassivi SD, Schild SE and Adjei AA: Non-small cell lung cancer: Epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 83:pp. 584–594. 2008; View Article : Google Scholar : PubMed/NCBI

4 

Mirsadraee S, Oswal D, Alizadeh Y, Caulo A and van Beek E Jr: The 7th lung cancer TNM classification and staging system: Review of the changes and implications. World J Radiol. 28:128–134. 2012.

5 

Tan Z, Yang C, Zhang X, Zheng P and Shen W: Expression of glucose transporter 1 and prognosis in non-small cell lung cancer: A pooled analysis of 1665 patients. Oncotarget. 8:60954–60961. 2017. View Article : Google Scholar : PubMed/NCBI

6 

Zhou J, Yu Y, Pei Y, Cao C, Ding C, Wang D, Sun L and Niu G: A potential prognostic biomarker SPC24 promotes tumorigenesis and metastasis in lung cancer. Oncotarget. 8:65469–65480. 2017.PubMed/NCBI

7 

Geiger JL, Grandis JR and Bauman JE: The STAT3 pathway as a therapeutic target in head and neck cancer: Barriers and innovations. Oral Oncol. 56:84–92. 2016. View Article : Google Scholar : PubMed/NCBI

8 

Banerjee K and Resat H: Constitutive activation of STAT3 in breast cancer cells: A review. Int J Cancer. 138:2570–2578. 2016. View Article : Google Scholar : PubMed/NCBI

9 

Wang H, Byfield G, Jiang Y, Smith GW, McCloskey M and Hartnett ME: VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. Am J Pathol. 180:1243–1253. 2012. View Article : Google Scholar : PubMed/NCBI

10 

Kondo S, Yoshizaki T, Wakisaka N, Horikawa T, Murono S, Jang KL, Joab I, Furukawa M and Pagano JS: MUC1 induced by Epstein-Barr virus latent membrane protein 1 causes dissociation of the cell-matrix interaction and cellular invasiveness via STAT signaling. J Virol. 81:1554–1562. 2007. View Article : Google Scholar : PubMed/NCBI

11 

Gendler SJ, Lancaster CA, Taylor-Papadimitriou J, Duhig T, Peat N, Burchell J, Pemberton L, Lalani EN and Wilson D: Molecular cloning and expression of human tumor-associated polymorphic epithelial mucin. J Biol Chem. 265:15286–15293. 1990.PubMed/NCBI

12 

Jarrard JA, Linnoila RI, Lee H, Steinberg SM, Witschi H and Szabo E: MUC1 is a novel marker for the type II pneumocyte ineage during lung carcinogenesis. Cancer Res. 58:5582–5589. 1998.PubMed/NCBI

13 

Ho SB, Niehans GA, Lyftogt C, Yan PS, Cherwitz DL, Gum ET, Dahiya R and Kim YS: Heterogeneity of mucin gene expression in normal and neoplastic tissues. Cancer Res. 53:641–651. 1993.PubMed/NCBI

14 

Mizoguchi M, Betensky RA, Batchelor TT, Bernay DC, Louis DN and Nutt CL: Activation of STAT3, MAPK, and AKT in malignant astrocytic gliomas: Correlation with EGFR status, tumor grade, and survival. J Neuropathol Exp Neurol. 65:1181–1188. 2006. View Article : Google Scholar : PubMed/NCBI

15 

Zhou W, Bi X, Gao G and Sun L: miRNA-133b and miRNA-135a induce apoptosis via the JAK2/STAT3 signaling pathway in human renal carcinoma cells. Biomed Pharmacother. 84:722–729. 2016. View Article : Google Scholar : PubMed/NCBI

16 

Yin Z, Zhang Y, Li Y, Lv T, Liu J and Wang X: Prognostic significance of STAT3 expression and its correlation with chemoresistance of non-small cell lung cancer cells. Acta Histochem. 114:151–158. 2012. View Article : Google Scholar : PubMed/NCBI

17 

Ai T, Wang Z, Zhang M, Zhang L, Wang N, Li W and Song L: Expression and prognostic relevance of STAT3 and cyclin D1 in non-small cell lung cancer. Int J Biol Markers. 27:e132–e138. 2012. View Article : Google Scholar : PubMed/NCBI

18 

Yu Y, Zhao Q, Wang Z and Liu XY: Activated STAT3 correlates with prognosis of non-small cell lung cancer and indicates new anticancer strategies. Cancer Chemother Pharmacol. 75:917–922. 2015. View Article : Google Scholar : PubMed/NCBI

19 

Wang RJ, Zhang JZ and Wang P: Expression of pSTAT3 in non-small cell lung cancer and its clinical significance. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 28:288–290. 2012.(In Chinese). PubMed/NCBI

20 

Xu YH and Lu S: A meta-analysis of STAT3 and phospho-STAT3 expression and survival of patients with non-small-cell lung cancer. Eur J Surg Oncol. 40:311–317. 2014. View Article : Google Scholar : PubMed/NCBI

21 

Lavrsen K, Madsen CB, Rasch MG, Woetmann A, Ødum N, Mandel U, Clausen H, Pedersen AE and Wandall HH: Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity. Glycoconj J. 30:227–236. 2013. View Article : Google Scholar : PubMed/NCBI

22 

Yang E, Hu XF and Xing PX: Advances of MUC1 as a target for breast cancer immunotherapy. Histol Histopathol. 22:905–922. 2007.PubMed/NCBI

23 

Yonezawa S, Kitajima S, Higashi M, Osako M, Horinouchi M, Yokoyama S, Kitamoto S, Yamada N, Tamura Y, Shimizu T, et al: A novel anti-MUC1 antibody against the MUC1 cytoplasmic tail domain: Use in sensitive identification of poorly differentiated cells in adenocarcinoma of the stomach. Gastric Cancer. 15:370–381. 2012. View Article : Google Scholar : PubMed/NCBI

24 

Wang XT, Kong FB, Mai W, Li L and Pang LM: MUC1 immunohistochemical expression as a prognostic factor in gastric cancer: Meta-analysis. Dis Markers. 2016:94215712016. View Article : Google Scholar : PubMed/NCBI

25 

Zhang K, Tang W, Qu X, Guo Q, Inagaki Y, Seyama Y, Abe H, Gai R, Kokudo N, Sugawara Y, et al: KL-6 mucin in metastatic liver cancer tissues from primary colorectal carcinoma. Hepatogastroenterology. 56:960–963. 2009.PubMed/NCBI

26 

Mizumoto M, Honjo G, Kobashi Y, Awane M and Matsusue S: Molecular profile of apomucin and p53 protein as predictors of malignancy in intraductal papillary mucinous neoplasms of the pancreas. Hepatogastroenterology. 58:1791–1795. 2011.PubMed/NCBI

27 

Hamada T, Nomura M, Kamikawa Y, Yamada N, Batra SK, Yonezawa S and Sugihara K: DF3 epitope expression on MUC1 mucin is associated with tumor aggressiveness, subsequent lymph node metastasis, and poor prognosis in patients with oral squamous cell carcinoma. Cancer. 118:5251–5264. 2012. View Article : Google Scholar : PubMed/NCBI

28 

Leroy X, Zerimech F, Zini L, Copin MC, Buisine MP, Gosselin B, Aubert JP and Porchet N: MUC1 expression is correlated with nuclear grade and tumor progression in pT1 renal clear cell carcinoma. Am J Clin Pathol. 118:47–51. 2002. View Article : Google Scholar : PubMed/NCBI

29 

Kaira K, Murakami H, Serizawa M, Koh Y, Abe M, Ohde Y, Takahashi T, Kondo H, Nakajima T and Yamamoto N: MUC1 expression in thymic epithelial tumors: MUC1 may be useful marker as differential diagnosis between type B3 thymoma and thymic carcinoma. Virchows Arch. 458:615–620. 2011. View Article : Google Scholar : PubMed/NCBI

30 

Situ D, Wang J, Ma Y, Zhu Z, Hu Y, Long H and Rong T: Expression and prognostic relevance of MUC1 in stage IB non-small cell lung cancer. Med Oncol. 28 Suppl 1:S596–S604. 2011. View Article : Google Scholar : PubMed/NCBI

31 

Demirag F, Cakir E, Bayiz H and Eren Yazici U: MUC1 and bcl-2 expression in preinvasive lesions and adenosquamous carcinoma of the lung. Acta Chir Belg. 113:19–24. 2013. View Article : Google Scholar : PubMed/NCBI

32 

Ahmad R, Rajabi H, Kosugi M, Joshi MD, Alam M, Vasir B, Kawano T, Kharbanda S and Kufe D: MUC1-C oncoprotein promotes STAT3 activation in an autoinductive regulatory loop. Sci Signal. 4:ra92011. View Article : Google Scholar : PubMed/NCBI

33 

Gao J, McConnell MJ, Yu B, Li J, Balko JM, Black EP, Johnson JO, Lloyd MC, Altiok S and Haura EB: MUC1 is a downstream target of STAT3 and regulates lung cancer cell survival and invasion. Int J Oncol. 35:337–345. 2009.PubMed/NCBI

Related Articles

Journal Cover

April 2018
Volume 15 Issue 4

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Sun, Z., Zhang, M., Yang, F., Gao, W., Wang, Z., & Zhu, L. (2018). Clinical and prognostic significance of signal transducer and activator of transcription 3 and mucin 1 in patients with non-small cell lung cancer following surgery. Oncology Letters, 15, 4278-4288. https://doi.org/10.3892/ol.2018.7858
MLA
Sun, Z., Zhang, M., Yang, F., Gao, W., Wang, Z., Zhu, L."Clinical and prognostic significance of signal transducer and activator of transcription 3 and mucin 1 in patients with non-small cell lung cancer following surgery". Oncology Letters 15.4 (2018): 4278-4288.
Chicago
Sun, Z., Zhang, M., Yang, F., Gao, W., Wang, Z., Zhu, L."Clinical and prognostic significance of signal transducer and activator of transcription 3 and mucin 1 in patients with non-small cell lung cancer following surgery". Oncology Letters 15, no. 4 (2018): 4278-4288. https://doi.org/10.3892/ol.2018.7858